CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies

Roch Houot; Holbrook Kohrt

doi:10.4161/21624011.2014.941740

CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies

Oncoimmunology. 2014 Jul 3;3(7):e941740. doi: 10.4161/21624011.2014.941740. eCollection 2014.

Authors

Roch Houot¹, Holbrook Kohrt²

Affiliations

¹ CHU Rennes; Service Hématologie Clinique ; Rennes, France ; INSERM ; Rennes, France.
² Department of Medicine, Division of Oncology; Stanford University ; Stanford, CA USA.

Abstract

Some evidence suggests that monoclonal antibodies (mAb) can induce an adaptive immune response against tumor cells ("vaccinal effect"). Recently, we have shown that an anti-CD137 mAb can enhance the "vaccinal effect" of an anti-tumor mAb (cetuximab), thereby transforming a passive, monoclonal, short-term immunotherapy into an active, polyclonal, long-lasting immune response.

Keywords: ADCC, antibody-dependent cellular cytotoxicity; Ag, antigens; CDC, complement-dependent cytotoxicity; CRC, colorectal cancer; DC, dendritic cells; FcR, Fc receptor; HN, head and neck; MHC, major histocompatibility complex; NK, natural killer; TCR, T cell receptor; antibody-dependent cell mediated cytotoxicity (ADCC); immunotherapy; mAb, monoclonal antibodies; monoclonal antibody; natural killer cells.